Cubist Systematic Strategies’s ProQR Therapeutics PRQR Stock Holding History

Cubist Systematic Strategies’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$111K	Buy	52,191 +48,130	+1,185%	+$105K	﹤0.01%	2761
2025 Q2	$8.28K	Sell	4,061 -85,584	-95%	-$139K	﹤0.01%	2843
2025 Q1	$119K	Sell	89,645 -44,045	-33%	-$93.8K	﹤0.01%	2613
2024 Q4	$354K	Buy	+133,690	New	+$424K	﹤0.01%	2332
2023 Q2	–	Sell	-101,003	Closed	-$215K	–	4147
2023 Q1	$215K	Buy	101,003 +15,756	+18%	+$48.2K	﹤0.01%	3191
2022 Q4	$315K	Buy	+85,247	New	+$112K	﹤0.01%	3332
2022 Q2	–	Sell	-14,400	Closed	-$13K	–	4519
2022 Q1	$13K	Buy	14,400 +13,697	+1,948%	+$45.9K	﹤0.01%	3487
2021 Q4	$6K	Sell	703 -24,058	-97%	-$183K	﹤0.01%	3407
2021 Q3	$207K	Sell	24,761 -12,923	-34%	-$84.4K	﹤0.01%	2568
2021 Q2	$254K	Buy	37,684 +22,339	+146%	+$144K	﹤0.01%	2427
2021 Q1	$101K	Buy	+15,345	New	+$78.4K	﹤0.01%	2640
2015 Q3	–	Sell	-936	Closed	-$16K	–	1978
2015 Q2	$16K	Sell	936 -12,128	-93%	-$228K	﹤0.01%	1762
2015 Q1	$286K	Buy	+13,064	New	+$270K	0.01%	1287

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cubist Systematic Strategies's PRQR Position: Q3 2025 in Review

Cubist Systematic Strategies increased its ProQR Therapeutics (PRQR) stake by 1,185% in Q3 2025, buying an estimated $105K and bringing the position to 52,191 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #2761.

Cubist Systematic Strategies first reported a position in PRQR in Q1 2015 and has held it in 13 quarters since. The position peaked at $354K in Q4 2024. 64 funds tracked by Wall St. Rank hold PRQR as of Q3 2025.

Cubist Systematic Strategies held 52,191 shares of ProQR Therapeutics worth $111K as of Q3 2025.
Cubist Systematic Strategies bought 48,130 ProQR Therapeutics shares in Q3 2025, an estimated $105K.
ProQR Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2761 holding.
Cubist Systematic Strategies first reported a position in ProQR Therapeutics in Q1 2015 and has held it in 13 quarters since.
Cubist Systematic Strategies's ProQR Therapeutics position peaked at $354K in Q4 2024.
64 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.